ENDRA Life Sciences (NDRA)
(Delayed Data from NSDQ)
$0.22 USD
-0.04 (-14.84%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $0.21 -0.01 (-4.20%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.22 USD
-0.04 (-14.84%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $0.21 -0.01 (-4.20%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Zacks News
Here's Why ENDRA Life Sciences Inc. (NDRA) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for ENDRA Life Sciences Inc. (NDRA), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Forget Bargains, Play 5 Stocks With Rising P/E Instead
by Sanghamitra Saha
Forget undervalued stocks, there is room for upside even in stocks with rising P/E.
ENDRA Life Sciences Inc. (NDRA) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
ENDRA Life Sciences Inc. (NDRA) delivered earnings and revenue surprises of 14.29% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights: MedTech, including Natus Medical, Owens & Minor, Penumbra, Apollo Medical and ENDRA Life Sciences
by Zacks Equity Research
Zacks Industry Outlook Highlights: MedTech, including Natus Medical, Owens & Minor, Penumbra, Apollo Medical and ENDRA Life Sciences
5 MedTech Outperformers With Nearly 40% or More Gain in 2021
by Debanjana Dey
Here are a few MedTech stocks, Natus Medical (NTUS), Owens & Minor (OMI), ENDRA Life Sciences (NDRA), Penumbra (PEN), Apollo Medical (AMEH), which might be prudent investment choices now.